Form 4: ResMed CFO Brett Sandercock Reports Acquisition of Shares Following Performance-Based Vesting

Chief Financial Officer of ResMed, Brett Sandercock, reports the acquisition of ResMed common stock following the vesting of performance-based restricted stock units.

Summary

• On August 15, 2024, Brett Sandercock, the Chief Financial Officer of ResMed Inc., acquired 7,915 shares of ResMed common stock.
• These shares were obtained through the vesting of performance-based restricted stock units granted on November 16, 2023.
• The compensation committee certified that the performance metrics were met, leading to the vesting of these units.
• An additional 841 shares were also acquired on the same date due to the performance metrics being met for that portion of the grant.
• These additional units are subject to a three-year time-vesting requirement from the grant date, contingent upon continued service.
• Following these transactions, Sandercock beneficially owns 97,812 shares of ResMed common stock directly.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The vesting of performance-based restricted stock units suggests that the company is meeting its performance goals, which is a positive indicator. The CFO's increased stake in the company further aligns his interests with shareholders.

Positives

• The vesting of performance-based restricted stock units indicates that performance metrics were successfully achieved.
• The CFO's increased stake in the company aligns his interests with those of the shareholders.

Future Outlook

The earned units remain subject to time-vesting requirements, and are scheduled to vest on the three-year anniversary of the grant, assuming continued service through the vesting date.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency regarding the alignment of management's interests with shareholders through equity-based compensation.

Comparison to Industry Standards

• Performance-based equity compensation is a common practice among publicly traded companies, particularly in the technology and healthcare sectors, to incentivize executives and align their interests with shareholder value creation.
• Companies like Medtronic, Stryker, and Philips also utilize similar compensation structures involving restricted stock units and performance-based incentives for their executive teams.
• The vesting schedules and performance metrics vary across companies, but the underlying principle of linking executive compensation to company performance remains consistent.

Stakeholder Impact

• Shareholders may view the vesting of performance-based restricted stock units as a positive sign, indicating that the company is achieving its performance targets.
• Employees may be motivated by the fact that executive compensation is tied to company performance.

Key Dates